Nuvalent Inc
NUVL
ISIN null / Valor 112589757
Nuvalent Inc
UMushroom community rating:
About company
Nuvalent Inc. is a biotechnology company focused on developing targeted therapies for patients with cancer.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (19.11.2025):
In Nuvalent Inc’s third quarter 2025 financial results, the company reported strong liquidity with a cash position of $943.1 million, supported by robust pipeline progress in targeted NSCLC therapies. The third quarter also reflected significant investments in research and development, with R&D expenses of $83.8 million, alongside general and administrative expenses of $28.9 million, contributing to a net loss of $122.4 million, while affirming a cash runway into 2028.
Cash Position
Nuvalent Inc reported a cash, cash equivalents, and marketable securities balance of $943.1 million for the third quarter of 2025, ensuring financial support for its current operating plan through 2028.
R&D Expenses
For the third quarter of 2025, R&D expenses were $83.8 million, underscoring the company’s commitment to advancing its clinical pipeline in NSCLC therapies.
General & Administrative Expenses
General and administrative expenses for Q3 2025 were $28.9 million, reflecting the ongoing costs associated with managing its operations during a critical phase of development.
Net Loss
The company reported a net loss of $122.4 million in the third quarter of 2025, a result of substantial investments in R&D and operational expenses tied to its progression towards a commercial stage biopharmaceutical company.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
7003 M
Market cap (USD)
205,560
Daily traded volume (Shares)
80.72 / 76.93
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
